101 related articles for article (PubMed ID: 22564276)
21. Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors.
Belal A
Bioorg Chem; 2015 Apr; 59():124-9. PubMed ID: 25748126
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y
Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of pyridoquinazoline derivatives as potent epidermal growth factor receptor inhibitors.
Rani S; Sridhar L; Srivastava R; Singh VK
Cancer Biother Radiopharm; 2013; 28(6):494-9. PubMed ID: 23641780
[TBL] [Abstract][Full Text] [Related]
25. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.
Coumar MS; Chu CY; Lin CW; Shiao HY; Ho YL; Reddy R; Lin WH; Chen CH; Peng YH; Leou JS; Lien TW; Huang CT; Fang MY; Wu SH; Wu JS; Chittimalla SK; Song JS; Hsu JT; Wu SY; Liao CC; Chao YS; Hsieh HP
J Med Chem; 2010 Jul; 53(13):4980-8. PubMed ID: 20550212
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of novel isatin-thiazoline and isatin-benzimidazole conjugates as anti-breast cancer agents.
Taher AT; Khalil NA; Ahmed EM
Arch Pharm Res; 2011 Oct; 34(10):1615-21. PubMed ID: 22076761
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, antitumor activity and SAR study of novel [1,2,4]triazino[4,5-a]benzimidazole derivatives.
El-Nassan HB
Eur J Med Chem; 2012 Jul; 53():22-7. PubMed ID: 22542105
[TBL] [Abstract][Full Text] [Related]
29. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.
Li S; Sun X; Zhao H; Tang Y; Lan M
Bioorg Med Chem Lett; 2012 Jun; 22(12):4004-9. PubMed ID: 22595177
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of some 1,2-disubstituted benzimidazole derivatives as new potential anticancer agents.
Yurttaş L; Demirayak Ş; Çiftçi GA; Yıldırım ŞU; Kaplancıklı ZA
Arch Pharm (Weinheim); 2013 May; 346(5):403-14. PubMed ID: 23526768
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives.
Luo Y; Xiao F; Qian S; Lu W; Yang B
Eur J Med Chem; 2011 Jan; 46(1):417-22. PubMed ID: 21115212
[TBL] [Abstract][Full Text] [Related]
33. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
El Ella DA; Saleh KA; Hassan M; Hamdy N; El-Araby ME; Abouzid KA
Arzneimittelforschung; 2012 Aug; 62(8):360-6. PubMed ID: 22723174
[TBL] [Abstract][Full Text] [Related]
35. 2-phenyl-1-[4-(2-piperidine-1-yl-ethoxy)benzyl]-1H-benzimidazoles as ligands for the estrogen receptor: synthesis and pharmacological evaluation.
Dettmann S; Szymanowitz K; Wellner A; Schiedel A; Müller CE; Gust R
Bioorg Med Chem; 2010 Jul; 18(14):4905-16. PubMed ID: 20598555
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
37. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
39. 2-Aminobenzimidazoles as potent Aurora kinase inhibitors.
Zhong M; Bui M; Shen W; Baskaran S; Allen DA; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris SO; Heumann SA; Hoch U; Ivy SN; Jacobs JW; Lam S; Lee H; McDowell RS; Oslob JD; Purkey HE; Romanowski MJ; Silverman JA; Tangonan BT; Taverna P; Yang W; Yoburn JC; Yu CH; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2009 Sep; 19(17):5158-61. PubMed ID: 19646866
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors.
Rae JM; Lippman ME
Breast Cancer Res Treat; 2004 Jan; 83(2):99-107. PubMed ID: 14997040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
